Shares of Monopar Therapeutics Inc. (MNPR) have gained 21.2% over the past four weeks to close the last trading session at $77.15, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $109.91 indicates a potential upside of 42.5%.The average comprises 11 short-term price targets ranging from a low of $85.00 to a high of $142.00, with a standard deviation of $17. While the lowest esti ...

Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the best hot stocks to invest in. On October 6, Raymond James raised the firm’s price target on Monopar Therapeutics to $142 from $80, while keeping a Strong Buy rating on the shares. The firm thinks that the company’s shares can continue to work well into 2026. Earlier in Q2 2025, the company’s net loss was $2.5 million (or $0.35 per share), compared to a net loss of $1.7 million (or $0.49 per share) for Q2 2024. Monopar Therapeutics reported that its cas ...

WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11 ...

市场展望与策略 - 首席市场策略师Ryan Detrick预计年底将出现强劲反弹，尽管9月末和10月初是季节性疲软时期，但第四季度历史中位数回报率仍接近6% [1] - 市场已连续5个月上涨，当市场在进入10月前连续上涨5个月时，第四季度绝大多数时间会表现更好 [1] - 看涨情绪基于动量因素，牛市仍具备动量 [1] - 市场欢迎4%至6%的正常温和回调，因股市每日上涨会引发紧张情绪 [2] - 认沽认购比率处于年内最低水平，且有580亿美元资金流入美国股票基金，为今年最大规模 [2] - 任何市场波动或疲软都被视为买入机会，驱动力包括强劲的盈利、利润率以及更强劲的消费者，并未看到有些人讨论的经济衰退 [2] 股票筛选方法 - 筛选标准为过去3个月表现超过50%且上涨潜力超过20%的热门股票 [5] - 从精英对冲基金最受欢迎且分析师看好的股票中选出12只，按持有它们的对冲基金数量升序排列 [5] - 数据截至2025年第二季度 [5] Monopar Therapeutics Inc (MNPR) - 截至10月10日，3个月股价表现达10082% [7] - 平均上涨潜力为2070%，有6家对冲基金持有 [8] - Raymond James于10月6日将目标价从80美元上调至142美元，维持强力买入评级，认为其股价表现可延续至2026年 [8] - 2025年第二季度净亏损250万美元（每股035美元），2024年同期净亏损为170万美元（每股049美元） [9] - 现金、现金等价物及投资总额为5330万美元，可支持运营至2026年12月31日 [9] - 公司为临床阶段生物制药公司，专注于开发癌症疗法，计划提交ALXN1840新药申请，完成MNPR-101-Zr的1期成像/剂量测定试验，继续MNPR-101-Lu的1a期治疗试验，并将临床前MNPR-101-Ac项目推进至临床阶段 [10] Mesoblast Limited (MESO) - 截至10月10日，3个月股价表现达6401% [11] - 平均上涨潜力为5616%，有6家对冲基金持有 [11] - 10月3日宣布其产品Ryoncil获得美国医疗保险与医疗补助服务中心分配的永久性J代码J3402，于10月1日生效，用于计费和报销 [11] - CMS的正式认可是一个商业里程碑，为Ryoncil提供了标准化、清晰的永久计费路径，便于医保、医疗补助和商业支付方报销，从而扩大患者对该疗法的可及性 [12] - Ryoncil是美国FDA批准的首个用于任何适应症的间充质基质细胞产品，也是唯一获批用于12岁以下儿童类固醇难治性急性移植物抗宿主病的产品 [13] - 公司开发用于严重炎症性疾病的同种异体（即用型）细胞药物，其专有间充质谱系细胞疗法技术平台通过释放抗炎因子来调节免疫系统，减少有害炎症过程 [13] - 公司及其子公司在澳大利亚、美国、新加坡和瑞士开发再生医学产品，其专有再生医学技术平台基于间充质谱系细胞 [14]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying MNPR stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

公司股价表现 - Monopar Therapeutics Inc 股价在过去一年出现巨大飙升 此前公司现金为710万美元 市值低于900万美元 [1] 公司业务发展 - 公司收购了威尔逊病候选药物ALXN-1840 [1] 投资论坛策略 - The Busted IPO Forum投资论坛专注于上市18个月至6年且股价显著低于发行价的股票 [1]

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

融资方案核心条款 - 公司进行承销注册发行，包括1,034,433股普通股，每股发行价为67.67美元，同时向特定投资者发行可购买960,542股普通股的预融资权证，每份权证购买价为67.669美元 [1] - 此次发行预计总毛收入（在扣除预期的股票回购后，但未扣除承销折扣和佣金及预计发行费用前）约为1亿美元 [2] - 公司计划使用高达3500万美元的发行收益，以每股63.6098美元的价格从Tactic Pharma, LLC处回购其普通股 [3] - 此次发行预计于2025年9月25日或前后完成 [3] 资金用途 - 发行所得的净收益将用于一般公司用途，可能包括研发支出、临床试验支出、产品生产和供应以及营运资金 [2] - 部分收益（高达3500万美元）将用于从Tactic Pharma, LLC回购公司普通股 [3] 承销商与法律文件 - 此次发行的联席账簿管理人为摩根士丹利、Leerink Partners和巴克莱 [4] - 证券发行依据一份于2025年8月29日提交、2025年9月9日生效的S-3表格储架注册声明进行 [5] 公司业务概览 - 公司为临床阶段生物制药公司，主要研发管线包括用于威尔逊病的晚期阶段药物ALXN1840，以及用于晚期癌症成像的1期阶段药物MNPR-101-Zr，用于晚期癌症治疗的1a期阶段药物MNPR-101-Lu和临床前晚期阶段药物MNPR-101-Ac225等放射性药物项目 [7]

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (link), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” Wilson dis ...

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (link), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” Wilson dis ...